share_log

Phio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Phio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Phio Pharmaceuticals | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/15 05:54

Moomoo AI 已提取核心訊息

Phio Pharmaceuticals reported Q3 2024 net loss of $1.52 million, compared to $2.78 million in Q3 2023, as research and development expenses decreased 64% to $644,000. The company ended the quarter with cash of $5.39 million, down from $8.49 million at year-end 2023.The significant reduction in R&D expenses reflects the company's transition from research to product development, including headcount reduction and termination of the AgonOx collaboration agreement in May 2024. The company is now focused on its Phase 1b clinical trial of PH-762 for skin cancer treatment, which has shown positive safety data in initial patient cohorts.Management expects current cash reserves to fund operations into Q2 2025 but notes substantial doubt about continuing as a going concern without additional funding. The company is evaluating financing options while advancing its lead candidate PH-762, which has demonstrated promising early clinical results with no serious adverse events reported in patients treated to date.
Phio Pharmaceuticals reported Q3 2024 net loss of $1.52 million, compared to $2.78 million in Q3 2023, as research and development expenses decreased 64% to $644,000. The company ended the quarter with cash of $5.39 million, down from $8.49 million at year-end 2023.The significant reduction in R&D expenses reflects the company's transition from research to product development, including headcount reduction and termination of the AgonOx collaboration agreement in May 2024. The company is now focused on its Phase 1b clinical trial of PH-762 for skin cancer treatment, which has shown positive safety data in initial patient cohorts.Management expects current cash reserves to fund operations into Q2 2025 but notes substantial doubt about continuing as a going concern without additional funding. The company is evaluating financing options while advancing its lead candidate PH-762, which has demonstrated promising early clinical results with no serious adverse events reported in patients treated to date.
Phio Pharmaceuticals報告2024年第三季度淨虧損152萬美元，較2023年第三季度的278萬美元有所減少，因爲研究和開發費用減少了64%，降至644,000美元。公司在本季度結束時擁有現金539萬美元，低於2023年年末的849萬美元。研發費用的顯著減少反映了公司從研究轉向產品開發的過渡，包括減少員工人數和在2024年5月終止與AgonOx的合作協議。公司目前專注於PH-762治療皮膚癌的10億階段臨牀試驗，初期患者隊列顯示出積極的安全性數據。管理層預計當前現金儲備將能夠支持運營至2025年第二季度，但指出在沒有額外資金的情況下繼續作爲持續經營存在重大懷疑。公司正在評估融資期權，同時推進其領先候選藥物PH-762，該藥物在至今治療的患者中表現出有前景的早期臨牀結果，且未報告嚴重不良事件。
Phio Pharmaceuticals報告2024年第三季度淨虧損152萬美元，較2023年第三季度的278萬美元有所減少，因爲研究和開發費用減少了64%，降至644,000美元。公司在本季度結束時擁有現金539萬美元，低於2023年年末的849萬美元。研發費用的顯著減少反映了公司從研究轉向產品開發的過渡，包括減少員工人數和在2024年5月終止與AgonOx的合作協議。公司目前專注於PH-762治療皮膚癌的10億階段臨牀試驗，初期患者隊列顯示出積極的安全性數據。管理層預計當前現金儲備將能夠支持運營至2025年第二季度，但指出在沒有額外資金的情況下繼續作爲持續經營存在重大懷疑。公司正在評估融資期權，同時推進其領先候選藥物PH-762，該藥物在至今治療的患者中表現出有前景的早期臨牀結果，且未報告嚴重不良事件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Solid Biosciences
    SLDB
    -- 6.6701
    Pulmatrix
    PULM
    -- 9.790
    Aditxt
    ADTX
    -- 0.0859
    萊斯康製藥
    LXRX
    -- 0.946
    Chimerix
    CMRX
    -- 5.000
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！